Business Wire

Thales Prepares to Secure European Infrastructures Against Attacks From Future Quantum Computers

14.4.2023 15:03:00 EEST | Business Wire | Press release

Share

As a driving force in the second quantum revolution, Thales has joined forces with around twenty deep tech, academic and industry partners, as part of the EuroQCI initiative (European Quantum Communication Infrastructure), which aims to deploy a quantum communication infrastructure for EU member states within three years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230414005211/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Carlos Castilla

By 2040, quantum computers could use their unprecedented computational power to decode encrypted data, incomparably threatening the security of even the best-protected communication systems. EuroQCI aims to counter that threat by developing sovereign systems to protect the communications and data assets of critical infrastructure providers and government institutions.

The longer-term objective of the initiative is to create a Quantum Information Network (QIN) that will harness the phenomenon of quantum entanglement not only to guarantee communications security but also to create networks of quantum sensors and processors, which have the potential to drive exponential increases in the already outstanding performance of quantum sensors and quantum computers.

As part of this effort, today, Thales is breaking new ground as a member of multiple new consortia that have been set up since late 2022 in these domains:

  • Quantum repeaters, with the Delft University: QIA (Quantum Internet Alliance) – led by the Delft University of Technology in the Netherlands – is working to demonstrate the feasibility of connecting users in two metropolitan areas 500 km apart, using quantum repeaters, which can compensate for the loss of information via a quantum memory;
  • Quantum key distribution: QKISS – coordinated by Exail – and QUARTER – led by LuxQuanta – are developing Quantum Key Distribution systems to protect users' critical communications from cyberattacks.
  • Certification of quantum communication: PETRUS – led by Deutsche Telekom – is the official coordinator of 32 EuroQCI projects, on behalf of the European Commission. It is also developing a framework for certification and accreditation of quantum communication products and networks.
  • Satellites quantum communications: TeQuantS – led by Thales Alenia Space – aims at developing quantum space-to-Earth communications technologies, necessary for cybersecurity applications and future quantum information networks, through the construction of satellites and optical ground stations by the end of 2026.

Specifically, the Thales teams taking part in these projects are working to develop quantum key generation, distribution and management equipment and the associated communication encryption devices, as well as defining the architecture of these quantum communication infrastructures.

Thales operates the largest quantum physics research facilities in Europe, in partnership with the CNRS, and some 100 engineers and researchers are currently engaged in the development of the quantum solutions (sensors, communications and algorithms) that will play a foundational role in tomorrow's world. These new consortia will all benefit from Thales's multi-disciplinary expertise, in particular in the field of secure communication networks.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS

Thales, Media Relations
Philomène Emptaz
philomene.emptaz@thalesgroup.com
06. 59. 06. 98. 76

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit

Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release

Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye